Download PDF
Thromb Haemost 1999; 82(02): 953-962
DOI: 10.1055/s-0037-1615938
Research Article
Schattauer GmbH

Do Interventions Provide Additional Benefit to Drug Treatment of Acute Coronary Syndromes? A Call for a Reserved, Watchful Approach

Dietrich C. Gulba
1   Charité - Humboldt University at Berlin, Franz Volhard Clinic, Berlin, GERMANY
› Author Affiliations
Further Information

Publication History

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

Introduction

Balloon angioplasty has revolutionized clinical cardiology since its first use in coronary patients by Andreas Grünzig in 1977.1 Initially limited to single, concentric, and proximal lesions, its clinical applicability rapidly expanded to more complex stenoses and total occlusions. With equipment improvement and growing investigator experience, even the most vulnerable lesions found in patients with unstable angina or acute myocardial infarction, were soon recognized as potential targets for percutaneous interventions.2-6 The overwhelming and unquestioned success of coronary angioplasty is most prominently demonstrated by the estimated more than 1,000,000 procedures that will be performed worldwide during 1999.

There is little doubt that, in patients with severe coronary lesions and exercise-induced angina, coronary angioplasty with minimal invasiveness can widen the vessel lumen and initiate coronary remodeling. This will lead, in many cases, to a durable relief from angina symptoms, as reviewed elsewhere.7 However, though vigorously advocated by interventional cardiologists, the benefit of percutaneous revascularization procedures in patients with acute coronary syndromes is less clear. This is even reflected in the AHCPR Clinical Practice Guidelines, 8 in which both conservative medical management and early invasive therapies are regarded as suitable alternatives in most patients. This chapter will address the question of whether and when coronary angioplasty will add to the benefits of conservative drug treatment.

 

  • References

  • 1 Grüntzig AR. Transluminal dilatation of coronary artery stenosis. Lancet 1978; I: 263.
    PubMedGoogle Scholar
  • 2 Rentrop KP, Blanke H, Karsch KR, Kreuzer H. Initial experience with transluminal recanalization of the recently occluded infarctrelated coronary artery in acute myocardial infarction: comparison with conventionally treated patients. Clin Cardiol 1979; 2: 92-105.
    CrossrefPubMedGoogle Scholar
  • 3 de Feyter PJ, Serruys PW, Wijns W, Van den Brand M. Emergency PTCA in unstable angina pectoris refractory to optimal medical treatment. N Engl J Med 1985; 313: 342-346.
    CrossrefPubMedGoogle Scholar
  • 4 de Feyter PJ, Serruys PW, Soward A, Van den Brand M, Bos E, Hugenholtz PG. Coronary angioplasty for early post-infarction unstable angina. Circulation 1986; 74: 1365-1370.
    CrossrefPubMedGoogle Scholar
  • 5 Meyer J, Merx W, Schmitz H, Erbel R, Kiesslich T, Dörr R, Lambertz H, Bethge C, Krebs W, Bardos P, Minale C, Mesmer BJ, Effert S. Percutaneous transluminal coronary angioplasty immediately after intracoronary streptolysis of transmural myocardial infarction. Circulation 1982; 66: 905-913.
    CrossrefPubMedGoogle Scholar
  • 6 Stone GW, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Ligon RW, Hartzler GO. Direct coronary angioplasty in acute myocardial infarction: outcome in patients with single vessel disease. J Am Coll Cardiol 1990; 15: 534-543.
    CrossrefPubMedGoogle Scholar
  • 7 Ellis SG. Elective coronary angioplasty: technique and complications. In: Topol EJ, ed. Textbook of interventional cardiology. 2nd ed.. Philadelphia: Saunders; 1994: 186-206.
    Google Scholar
  • 8 Braunwald E, Jones RH, Mark DB, Brown J, Brown L, Cheitlin MD, Concannon CA, Cowan M, Edwards C, Fuster V, Goldman L, Green LA, Grines CL, Lytle BW, McCauley KM, Mushlin AI, Rose GC, Smith III EE, Swain JA, Topol EJ, Willerson JT. Diagnosing and managing unstable angina. Circulation 1994; 90: 613-622.
    CrossrefPubMedGoogle Scholar
  • 9 Braunwald E. Unstable angina: classification. Circulation 1989; 80: 410-414.
    CrossrefPubMedGoogle Scholar
  • 10 Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or I. N Engl J Med 1997; 337: 1648-1653.
    CrossrefPubMedGoogle Scholar
  • 11 Newby LK, Christenson RH, Ohman M, Armstrong PW, Thompson TD, Lee KL, Hamm CW, Katus HA, Cianciolol C, Granger CB, Topol EJ, Califf RM. for the GUSTO-IIa Investigators. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. Circulation 1998; 98: 1853-1859.
    CrossrefPubMedGoogle Scholar
  • 12 Gottlieb SO, Weisfeldt ML, Ouyang P, Mellits ED, Gerstenblith G. Silent ischemia as a marker for early unfavourable outcomes in patients with unstable angina. N Engl J Med 1986; 312: 1214-1219.
    PubMedGoogle Scholar
  • 13 Dellborg M, Malmberg K, Rydén L, Svensson A-M, Swedberg K. Dynamic on-line vectorcardiography improves and simplifies inhospital ischemia monitoring of patients with unstable angina. J Am Coll Cardiol 1995; 26: 1501-1507.
    CrossrefPubMedGoogle Scholar
  • 14 Cairns JA, Gent M, Singer J, Finnie KJ, Frogatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG, Sackett DL, Sealy BJ, Tanser PH. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 1985; 313: 1369-1375.
    CrossrefPubMedGoogle Scholar
  • 15 The RISC Study Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary disease. Lancet 1990; 336: 827-830.
    CrossrefPubMedGoogle Scholar
  • 16 Thèroux P, Ouimet H, McCans J, Latour J, Joly P, Lévy G, Pelletier E, Rinzler D, Waters DD. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-1111.
    CrossrefPubMedGoogle Scholar
  • 17 Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, Pasotti C, Rudelli G. and the Studio della Ticlopidina nell’Angina Instabile Group. Antiplatelet treatment with ticlopidine in unstable angina — A controlled multicenter clinical trial. Circulation 1990; 82: 17-26.
    CrossrefPubMedGoogle Scholar
  • 18 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
    CrossrefPubMedGoogle Scholar
  • 19 Théroux P, Kouz S, Knudtson ML, Kells C, Nasmith J, Roy L, Dalle Ave S, Steiner B, Xiao Z, Rapold HJ. A randomized double-blind controlled trial with the non-peptidic platelet GP IIb/IIIa antagonist RO 44-9883 in unstable angina. Circulation 1994; 90 I. I-232. (Abstract)
    PubMedGoogle Scholar
  • 20 Davies MJ, Thomas AC. Plaque fissuring —the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 1985; 53: 363-373.
    CrossrefPubMedGoogle Scholar
  • 21 Davies MJ, Thomas AC. The pathophysiological basis and microanatomy of occlusive thrombosis formation in human coronary arteries. Philos Trans R Soc Lond B 1984; 294: 225-229.
    PubMedGoogle Scholar
  • 22 Fuster V, Stein B, Badimon L, Badimon JJ, Ambrose JA, Chesebro JH. Atherosclerotic plaque rupture and thrombosis: evolving concepts. Circulation 1990; 82 suppl. II II-47-II-59.
    PubMedGoogle Scholar
  • 23 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-250.
    CrossrefPubMedGoogle Scholar
  • 24 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 92: 310-318.
    PubMedGoogle Scholar
  • 25 Mann J, Davies M. Vulnerable plaque. Relation of characteristics to degree of stenosis in human coronary arteries. Circulation 1996; 94: 928-931.
    CrossrefPubMedGoogle Scholar
  • 26 Farb A, Burke AP, Tang AL, Liang Y, Mannan P, Smialek J, Virmani R. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996; 93: 1354-1363.
    CrossrefPubMedGoogle Scholar
  • 27 Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie GG, van der Meer J, Olaisson E, Undeland S, Ludwig K. for the FRIC Investigators. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary disease. Circulation 1997; 96: 61-68.
    CrossrefPubMedGoogle Scholar
  • 28 The FRISC Study Group. Low molecular weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-568.
    CrossrefPubMedGoogle Scholar
  • 29 Cohen M, Demers C, Gurfinkel EP, Turpie GG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premmereur J, Bigonzi F. for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-452.
    CrossrefPubMedGoogle Scholar
  • 30 Hirsh J. Low-molecular-weight heparin. A review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Circulation 1998; 98: 1575-1582.
    CrossrefPubMedGoogle Scholar
  • 31 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-782.
    CrossrefPubMedGoogle Scholar
  • 32 Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation. A pilot study. Circulation 1997; 96: 769-777.
    CrossrefPubMedGoogle Scholar
  • 33 Gulba DC, Huber K, Moll S, Dietz R. Platelet inhibition: new agents, new strategies, new trials. Fibrinolysis & Proteolysis 1998; 12 (Suppl. 02) 13-23.
    PubMedGoogle Scholar
  • 34 The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-443.
    CrossrefPubMedGoogle Scholar
  • 35 The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with Tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-1497.
    CrossrefPubMedGoogle Scholar
  • 36 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
    CrossrefPubMedGoogle Scholar
  • 37 The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB trial. Circulation 1994; 89: 1545-1556.
    CrossrefPubMedGoogle Scholar
  • 38 Boden WE, O’Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG, Wexler LF, Kleiger RE, Pepine CJ. for the VANQWISH trial investigators. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med 1998; 338: 1785-1792.
    CrossrefPubMedGoogle Scholar
  • 39 Yusuf S, Flather M, Pogue J, Hunt D, Varigos J, Piegas L, Avezum A, Anderson J, Keltai M, Budja A, Fox K, Ceremuzynski L. for the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry Investigators. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. Lancet 1998; 352: 507-514.
    CrossrefPubMedGoogle Scholar
  • 40 Suryapranata H, de Feyter P, Serruys P. Coronary angioplasty in patients with unstable angina pectoris: is there a role for thrombolysis?. J Am Coll Cardiol 1988; 12 (06) 69A-77A.
    CrossrefPubMedGoogle Scholar
  • 41 Arora RR, Platko WP, Bhadwar K, Simpfendorfer C. The role of intracoronary thrombus in acute complications during percutaneous transluminal coronary angioplasty. Cathet Cardiovasc Diagn 1989; 16: 226.
    CrossrefPubMedGoogle Scholar
  • 42 The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997; 349: 1422-1428.
    CrossrefPubMedGoogle Scholar
  • 43 The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-1453.
    CrossrefPubMedGoogle Scholar
  • 44 The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429-1435.
    CrossrefPubMedGoogle Scholar
  • 45 Gulba DC, Bode C, Runge MS, Huber K. Thrombolytic agents — an updated overview. Fibrinolysis & Proteolysis 1998; 12 (Suppl. 02) 39-58.
    PubMedGoogle Scholar
  • 46 Huber K, Runge MS, Bode C, Gulba D. Thrombolytic therapy in acute myocardial infarction —update 1996. Ann Hematol 1996; 73 suppl. I S29-S38.
    CrossrefPubMedGoogle Scholar
  • 47 Grines CL. Primary angioplasty —the strategy of choice. N Engl J Med 1996; 335: 1313-1315.
    PubMedGoogle Scholar
  • 48 Every NR, Parsons LS, Hlatky M, Martin JS, Weaver WDW. for the Myocardial Infarction Triage and Intervention Investigators. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med 1996; 335: 1253-1260.
    CrossrefPubMedGoogle Scholar
  • 49 The Global Use of Strategies to Open Occluded coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A Clinical trial comparing primary coronary angioplasty with tissue type plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336: 1621-1628.
    CrossrefPubMedGoogle Scholar
  • 50 Simoons ML, Arnold AER, Betriu A, DeBono DP, Col J, Dougherty FC, von Essen R, Lambertz H, Lubsen J, Meier B, Michel PL, Raynaud P, Rutsch W, Sanz GA, Schmidt W, Serruys PW, Thery C, Uebis R, Vahanian A, van de Werf F, Willems GM, Wood D, Verstraete M. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988; I: 197-203.
    PubMedGoogle Scholar
  • 51 The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med 1989; 320: 618-627.
    CrossrefPubMedGoogle Scholar
  • 52 Topol EJ, Califf RM, Kereiakes DJ, George BS. Thrombolysis and angioplasty in myocardial infarction (TAMI) trial. J Am Coll Cardiol 1987; 10 B 65B-74B.
    CrossrefPubMedGoogle Scholar
  • 53 Gulba D, Barthels M, Reil G-H, Lichtlen P. Thrombin-antithrombin-III-complex level as early predictor of reocclusion after successful thrombolysis. Lancet 1988; 2: 97.
    PubMedGoogle Scholar
  • 54 Gulba DC, Barthels M, Westhoff-Bleck M, Jost S, Rafflenbeul W, Daniel WG, Hecker H, Lichtlen PR. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy. Circulation 1991; 83: 937-944.
    CrossrefPubMedGoogle Scholar
  • 55 Gulba DC, Bode C, Topp J, Höpp H-W, Westhoff-Bleck M, Rafflenbeul W, Lichtlen PR. Die Häufigkeit von Residualthromben nach erfolgreicher Thrombolysetherapie bei akutem Herzinfarkt und ihre Bedeutung für die Rate früher Reokklusionen. Ein Bericht der multizentrischen Dosisfindungsstudie zur Thrombolysetherapie mit Urokinase-präaktivierter natürlicher Prourokinase (TCL 598). Z Kardiol 1990; 79: 279-285.
    PubMedGoogle Scholar
  • 56 Gulba DC, Daniel WG, Simon R, Jost S, Barthels M, Amende I, Rafflenbeul W, Lichtlen PR. Role of thrombolysis and thrombin in patients with acute coronary occlusion during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1990; 80: 1-5.
    PubMedGoogle Scholar
  • 57 Rapold HJ, de Bono D, Arnold AER, Arnout J, de Cock F, Collen D, Verstraete M. for the European Cooperative Study Group. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. Circulation 1992; 85: 928-934.
    CrossrefPubMedGoogle Scholar
  • 58 Califf RM, Topol EJ, Stack RS, Ellis SG, George BS, Kereiakes DJ, Samaha JK, Worley SJ, Anderson JL, Harrelson-Woodlief L, Wall TC, Phillips III HR, Abbottsmith CW, Candela RJ, Flanagan WH, Sasahara AA, Mantell SJ, Lee KL. for the TAMI Study Group. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of Thrombolysis and Angioplasty in Myocardial Infarction - Phase 5 randomized trial. Circulation 1991; 83: 1543-1556.
    CrossrefPubMedGoogle Scholar
  • 59 Falk E, Shah PK, Fuster V. Coronary Plaque Disruption. Circulation 1995; 92: 657-671.
    CrossrefPubMedGoogle Scholar
  • 60 Soward AL, Essed CE, Serruys PW. Coronary arterial findings after accidental death immediately after successful percutaneous transluminal coronary angioplasty. Am J Cardiol 1985; 56: 764.
    CrossrefPubMedGoogle Scholar
  • 61 Block PC, Myler RK, Stertzer S, Fallon JT. Morphology after transluminal coronary angioplasty in human beings. N Engl J Med 1981; 305: 382.
    CrossrefPubMedGoogle Scholar
  • 62 Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. and the INTACT Group. Retardation of coronary artery disease in man by the Ca-channel-blocker Nifedipine: results of INTACT. Lancet 1990; 335: 1109-1113.
    CrossrefPubMedGoogle Scholar
  • 63 Quinn TG, Alderman EL, McMillan A, Haskell W. for the SCRIP Investigators. Development of new coronary arteriosclerotic lesions during a 4-year multifactorial reduction program: the Stanford coronary risk intervention project (SCRIP). J Am Coll Cardiol 1994; 24: 900-908.
    CrossrefPubMedGoogle Scholar
  • 64 Brouwer MA, Böhncke JR, Veen G, Meijer A, van Eenige MJ, Verheugt WA. Adverse long-term effects of reocclusion after coronary thrombolysis. J Am Coll Cardiol 1995; 26: 1440-1444.
    CrossrefPubMedGoogle Scholar
  • 65 Takens BH, Brügemann J, van der Meer J, den Heijer P, Lie KI. Reocclusion three month after successful thrombolytic treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activating complex. Am J Cardiol 1990; 65: 1422-1424.
    CrossrefPubMedGoogle Scholar
  • 66 The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of Aspirin plus Tirofiban with Aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-1505.
    CrossrefPubMedGoogle Scholar
  • 67 Anand SS, Yusuf S, Pogue J, Weitz JI, Flather M. for the OASIS Pilot Study Investigators. Long-term, oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction. Organization to assess strategies for ischemic syndromes (OASIS) pilot study results. Circulation 1998; 98: 1064-1070.
    CrossrefPubMedGoogle Scholar
  • 68 Glick A, Kornowski R, Michowich Y, Koifman B, Roth A, Laniado S, Keren G. Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 1996; 77: 1145-1148.
    CrossrefPubMedGoogle Scholar
  • 69 Kereiakes DJ, Kleiman NS, Ferguson JJ, Masud ARZ, Broderick TM, Abbottsmith CW, Runyon JP, Anderson LC, Anders RJ, Dreiling RJ, Hantsbarger GL, Bryzinski B, Topol EJ. for the Oral Glycoprotein IIb/IIIa Receptor Blockade to Inhibit Thrombosis (ORBIT) Trial Investigators. Pharmacodynamic efficacy, clinical safety, and outcomes after prolongs platelet glycoprotein IIb/IIIa receptor blockade with oral Xemilofiban. Results of a multicenter, placebo-controlled, randomized trial. Circulation 1998; 98: 1268-1278.
    CrossrefPubMedGoogle Scholar
  • 70 Kereiakes DJ, Kleiman N, Ferguson JJ, Runyon JP, Broderieck TM, Higby NA, Martin LH, Hantsbarger G, McDonald S, Anders RJ. Sustained platelet glycoprotein IIb/IIIa blockade with oral Xemilofiban in 170 patients after coronary stent deployment. Circulation 1997; 96: 1117-1121.
    CrossrefPubMedGoogle Scholar
  • 71 Narjes H, Weisenberg H, Müller TH, Deichsel G, Krause J. Tolerability and platelet fibrinogen receptor occupancy (FRO) after oral treatment with BIBU 104 XX in healthy volunteers. Thromb Haemost 1995; 73 suppl. 1315. (Abstract)
    PubMedGoogle Scholar
  • 72 Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 1989; 9 suppl. I 119 1989.
    PubMedGoogle Scholar
  • 73 Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJ. for the Mayo Coronary Care Unit and Catheterization Laboratory Groups. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993; 328: 685-691.
    CrossrefPubMedGoogle Scholar
  • 74 The GUSTO Angiographic Investigators. The effect of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1622.
    CrossrefPubMedGoogle Scholar
  • 75 Gulba DC, Tanswell P, Dechend R, Sosada M, Weis A, Waigand J, Uhlich F, Hauck S, Jost S, Rafflenbeul W, Lichtlen PR, Dietz R. Sixty minutes alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction. J Am Coll Cardiol 1997; 30: 1611-1617.
    CrossrefPubMedGoogle Scholar